GILOTRIF vs VIZIMPRO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. GILOTRIF and VIZIMPRO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GILOTRIF	VIZIMPRO
Rating	72/100	64/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	AFATINIB DIMALEATE	DACOMITINIB
Manufacturer	Boehringer Ingelheim	Pfizer
Dosage forms	Tablet	Tablet
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma	Non-Small-Cell Lung Carcinoma

gilotrif vizimpro

Rating

72/100

64/100

Pharmacy pays

—

Type

Active ingredient

AFATINIB DIMALEATE

DACOMITINIB

Manufacturer

Boehringer Ingelheim

Pfizer

Dosage forms

Tablet

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Gilotrif or Vizimpro?

By our independent rating, Gilotrif scores higher — 3.6 vs 3.2 out of 5 for Vizimpro. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Gilotrif and Vizimpro?

Gilotrif contains Afatinib Dimaleate, while Vizimpro contains Dacomitinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.